(Q36819607)

16 August 2017

Clinical effects of adalimumab treatment with concomitant azathioprine in Japanese Crohn's disease patients (English)

1 reference

16 August 2017

0 references

0 references

1 reference

Kumi Ishida

1

1 reference

16 August 2017

Takuya Inoue

2

1 reference

16 August 2017

Kaori Fujiwara

3

1 reference

16 August 2017

Taisuke Sakanaka

4

1 reference

16 August 2017

Ken Narabayashi

5

1 reference

16 August 2017

Sadaharu Nouda

6

1 reference

16 August 2017

Toshihiko Okada

7

1 reference

16 August 2017

Kazuki Kakimoto

8

1 reference

16 August 2017

Takanori Kuramoto

9

1 reference

16 August 2017

Ken Kawakami

10

1 reference

16 August 2017

Yosuke Abe

11

1 reference

16 August 2017

Toshihisa Takeuchi

12

1 reference

16 August 2017

Mitsuyuki Murano

13

1 reference

16 August 2017

Satoshi Tokioka

14

1 reference

16 August 2017

Eiji Umegaki

15

1 reference

16 August 2017

Kazuhide Higuchi

16

1 reference

16 August 2017

language of work or name

English

0 references

publication date

1 May 2013

1 reference

World Journal of Gastroenterology

16 August 2017

1 reference

16 August 2017

19

1 reference

16 August 2017

17

1 reference

16 August 2017

2676-2682

1 reference

Current status of thiopurine analogues in the treatment in Crohn's disease.

16 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3645386

Loss of response and need for adalimumab dose intensification in Crohn's disease: a systematic review

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3645386

Immunomodulators for all patients with inflammatory bowel disease?

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3645386

Inflammatory bowel disease in the Asia-Pacific area: a comparison with developed countries and regional differences

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3645386

Incidence and clinical significance of immunogenicity to infliximab in Crohn's disease: a critical systematic review

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3645386

Certolizumab pegol for the treatment of Crohn's disease

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3645386

Adalimumab in patients with Crohn's disease--safety and efficacy in an open-label single centre study

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3645386

Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3645386

Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3645386

Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3645386

Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3645386

Infliximab maintenance therapy for fistulizing Crohn's disease

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3645386

Progress in searching for susceptibility gene for inflammatory bowel disease by positional cloning

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3645386

Inflammatory Bowel Disease

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3645386

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3645386

Biologic therapy of inflammatory bowel disease.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3645386

Infliximab for the treatment of fistulas in patients with Crohn's disease

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3645386

Increased production of tumour necrosis factor-alpha interleukin-1 beta, and interleukin-6 by morphologically normal intestinal biopsies from patients with Crohn's disease

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3645386

Long-term efficacy of adalimumab in paediatric Crohn's disease patients naïve to other anti-TNF therapies

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3645386

Tumour necrosis factor and Crohn's disease

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3645386

Does co-treatment with immunosuppressors improve outcome in patients with Crohn's disease treated with adalimumab?

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3645386

Early clinical remission and normalisation of CRP are the strongest predictors of efficacy, mucosal healing and dose escalation during the first year of adalimumab therapy in Crohn's disease.

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3645386

Association analysis of the NOD2 gene with susceptibility to graft-versus-host disease in a Japanese population.

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3645386

Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3645386

Clinical trial: benefits and risks of immunomodulators and maintenance infliximab for IBD-subgroup analyses across four randomized trials

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3645386

Efficacy and safety of azathioprine maintenance therapy in a group of Crohn's disease patients in China

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3645386

Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3645386

A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3645386

Infliximab, azathioprine, or combination therapy for Crohn's disease

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3645386

Usefulness of co-treatment with immunomodulators in patients with inflammatory bowel disease treated with scheduled infliximab maintenance therapy

20 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3645386

Influence of Trough Serum Levels and Immunogenicity on Long-term Outcome of Adalimumab Therapy in Crohn's Disease

4 December 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3645386

Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease

4 December 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3645386

CARD15/NOD2 mutational analysis in Japanese patients with Crohn's disease

4 December 2018

1 reference

12 December 2020

Immunogenicity negatively influences the outcome of adalimumab treatment in Crohn's disease

1 reference

12 December 2020

Efficacy and safety of short-term adalimumab treatment in patients with active Crohn's disease who lost response or showed intolerance to infliximab: a prospective, open-label, multicentre trial

1 reference

12 December 2020

Predictors of dose escalation of adalimumab in a prospective cohort of Crohn's disease patients

1 reference

12 December 2020

An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn's disease

1 reference

12 December 2020

Identifiers

DOI

10.3748/WJG.V19.I17.2676

1 reference

16 August 2017

1 reference

16 August 2017

PubMed publication ID

23674875

1 reference